---
title: "M Stanley: China AI Drug R&D Financing Accelerates, GENSCRIPT BIO  Benefits from Wet Lab Demand"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304828812.md"
description: "Morgan Stanley reports China's AI drug discovery financing surged 312% YoY to RMB15.8 billion in the first nine months, favoring leading platforms. This growth expands demand for wet lab services, benefiting GENSCRIPT BIO, which expects AIDD revenue to more than double by 2027. The bank maintains an 'Attractive' industry outlook. Meanwhile, GENSCRIPT BIO shares rose 3.09% to HKD31.32."
datetime: "2026-11-09T09:20:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304828812.md)
  - [en](https://longbridge.com/en/news/304828812.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304828812.md)
generator: "portal-rs"
---

# M Stanley: China AI Drug R&D Financing Accelerates, GENSCRIPT BIO  Benefits from Wet Lab Demand

Morgan Stanley released a research report stating that private financing for China's AI-aided drug discovery (AIDD) companies reached RMB15.8 billion in the first nine months of this year, representing a 312% YoY increase on an annualized basis, involving a total of 57 financing rounds. Investors remain selective, favoring leading platforms with molecular design capabilities.

The bank believes molecular design is relatively mature, while structured data and rapid experimental feedback help model training and validation. However, development capability remains more difficult to predict. AIDD is expected to raise drug development success rates from the current 6% to 8% to double-digit percentages, although clinical success remains the ultimate validation, and most AI-designed drug candidates are still in early-stage development.

As AIDD companies improve their ability to generate candidate binding molecules, demand is expanding from gene synthesis and protein expression to binding assays, functional validation and developability testing, creating opportunities for wet lab service providers such as GENSCRIPT BIO (01548.HK) +0.940 (+3.094%) Short selling $245.43M; Ratio 20.529% . The company expects AIDD revenue in 2027 to more than double from 2026. The bank maintains an "Attractive" industry outlook.

GENSCRIPT BIO (01548.HK) +0.940 (+3.094%) Short selling $245.43M; Ratio 20.529% closed at HKD31.32 today, up 3.09%, with trading volume of 37.8359 million shares and turnover of HKD1.195 billion. (da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-09 16:25.)

### Related Stocks

- [01548.HK](https://longbridge.com/en/quote/01548.HK.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)

## Related News & Research

- [AIâs billions and slick pledges heap pressure on pharma veterans](https://longbridge.com/en/news/306270834.md)
- [Huatai Raises GENSCRIPT B-1K  Earnings Forecasts on AIDD Benefits, Reiterates Buy](https://longbridge.com/en/news/304381452.md)
- [Zoomability Announces Availability of Q3 2026 Report](https://longbridge.com/en/news/306354193.md)
- [Nio Firefly debuts Haven special edition in Oslo, plans spring 2027 launch in Europe](https://longbridge.com/en/news/306380548.md)
- [GENSCRIPT BIO Picks Up 5% after Lower Open](https://longbridge.com/en/news/296046962.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**